Announced
Completed
Financials
Tags
DNA sequencing technology
Cross Border
Private
Minority
United States
Single Bidder
Venture Capital
Biotechnology
Friendly
Acquisition
Private Equity
Completed
Synopsis
Venrock led a $276m Series C round in Element Biosciences, a developer of a new and disruptive DNA sequencing platform, with participation from Janus Henderson Investors, Logos Capital, Meritech Capital Partners, Counterpoint Global (Morgan Stanley), T. Rowe Price, Fidelity Management & Research Company, Foresite Capital, JS Capital Management and RA Capital Advisors. "Element will provide researchers with innovative technology choices and more flexible tools for scientific exploration. We are working to realize our vision of dramatically expanding access to high quality, low cost, easy-to-use genomics tools," Molly He, Element Biosciences CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.